ATXN3 and Huntington disease: As shown in Supplementary Fig. 2, these two groups of HD study participants were not significantly different for age-at-onset (Supplementary Fig. 2A) or residual age-at-onset (Supplementary Fig. 2B), arguing against modification of HD by the ATXN3 CAG repeats.